胰腺癌立体定向放射治疗上海专家共识

Branch Association of Radiation Oncology of Shanghai Medical Association Consensus on stereotactic body radiation therapy for pancreatic cancer

胰腺癌是严重威胁人类健康且致死率极高的恶性肿瘤,5年生存率仅9%。尽管免疫治疗和靶向治疗在其他肿瘤中取得了较好的疗效,但在胰腺癌中未能明显改善患者的预后。因此,手术、化疗和放疗仍然是胰腺癌主要的治疗方法。大部分患者初诊时,即为局部晚期或晚期胰腺癌,所以放疗是延长患者生存期和提高生活质量的重要措施之一。鉴于立体定向放疗逐步广泛地应用于胰腺癌治疗,有必要对其制定统一的共识。在上海市医学会放射治疗专委会的推动下,基于胰腺癌立体定向放疗最新研究和实践知识,并结合国情,我们制定了胰腺癌立体定向放射治疗上海专家共识。该共识旨在促进规范和标准化胰腺癌立体定向放疗,达到改善胰腺癌患者预后的目标。

Pancreatic cancer is a life-threatening and lethal malignancy with a 5-year survival rate of only approximately 9%.Despite that immunotherapy or targeted therapy has been confirmed effective in other cancers,limited survival benefits have been achieved in pancreatic cancer.Therefore,surgery,chemotherapy and radiotherapy are still the main regimens of pancreatic cancer.Owing to that most of the patients have locally advanced or advanced pancreatic cancer at the initial diagnosis,radiotherapy is a pivotal local therapy for prolonging patients'survival and improving the quality of life.Given that stereotactic body radiation therapy has been gradually used in the treatment of pancreatic cancer,a consensus on stereotactic body radiation therapy for pancreatic cancer is required.Under the promotion of Radiation Oncology Society of Shanghai Medical Association,the consensus on stereotactic body radiation therapy for pancreatic cancer has been formulated based on the latest research and practice in stereotactic body radiation therapy for pancreatic cancer combined with national conditions in China,aiming to promote the standardization of stereotactic body radiation therapy for pancreatic cancer,and eventually provide favorable outcomes for pancreatic cancer patients.